Precatheterization Use of P2Y12 Inhibitors in Non-ST-Elevation Myocardial Infarction Patients Undergoing Early Cardiac Catheterization and In-Hospital Coronary Artery Bypass Grafting: Insights From the National Cardiovascular Data Registry®
- PMID: 28939715
- PMCID: PMC5634296
- DOI: 10.1161/JAHA.117.006508
Precatheterization Use of P2Y12 Inhibitors in Non-ST-Elevation Myocardial Infarction Patients Undergoing Early Cardiac Catheterization and In-Hospital Coronary Artery Bypass Grafting: Insights From the National Cardiovascular Data Registry®
Abstract
Background: Current guidelines recommend early P2Y12 inhibitor administration in non-ST-elevation myocardial infarction, but it is unclear if precatheterization use is associated with longer delays to coronary artery bypass grafting (CABG) or higher risk of post-CABG bleeding and transfusion. This study examines the patterns and outcomes of precatheterization P2Y12 inhibitor use in non-ST-elevation myocardial infarction patients who undergo CABG.
Methods and results: Retrospective analysis was done of 20 304 non-ST-elevation myocardial infarction patients in the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry (2009-2014) who underwent catheterization within 24 hours of admission and CABG during the index hospitalization. Using inverse probability-weighted propensity adjustment, we compared time from catheterization to CABG, post-CABG bleeding, and transfusion rates between patients who did and did not receive precatheterization P2Y12 inhibitors. Among study patients, 32.9% received a precatheterization P2Y12 inhibitor (of these, 2.2% were given ticagrelor and 3.7% prasugrel). Time from catheterization to CABG was longer among patients who received precatheterization P2Y12 inhibitor (median 69.9 hours [25th, 75th percentiles 28.2, 115.8] versus 43.5 hours [21.0, 71.8], P<0.0001), longer for patients treated with prasugrel (median 114.4 hours [66.5, 155.5]) or ticagrelor (90.4 hours [48.7, 124.5]) compared with clopidogrel (69.3 [27.5, 114.6], P<0.0001). Precatheterization P2Y12 inhibitor use was associated with a higher risk of post-CABG major bleeding (75.7% versus 73.4%, adjusted odds ratio 1.33, 95% confidence interval 1.22-1.45, P<0.0001) and transfusion (47.6% versus 35.7%, adjusted odds ratio 1.51, 95% confidence interval 1.41-1.62, P<0001); these relationships did not differ among patients treated with clopidogrel, prasugrel, or ticagrelor.
Conclusions: Precatheterization P2Y12 inhibitor use occurs commonly among non-ST-elevation myocardial infarction patients who undergo early catheterization and in-hospital CABG. Despite longer delays to surgery, the majority of pretreated patients proceed to CABG <3 days postcatheterization. Precatheterization P2Y12 inhibitor use is associated with higher risks of postoperative bleeding and transfusion.
Keywords: Non‐ST‐segment elevation acute coronary syndrome; P2Y12; coronary artery bypass graft surgery.
© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
Figures


Comment in
-
To Pretreat or Not to Pretreat (With Oral P2Y12 Antagonists)? That is the Question.J Am Heart Assoc. 2017 Sep 22;6(9):e007288. doi: 10.1161/JAHA.117.007288. J Am Heart Assoc. 2017. PMID: 28939720 Free PMC article. No abstract available.
Similar articles
-
Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration.J Thorac Cardiovasc Surg. 2013 Nov;146(5):1259-1266, 1266.e1; discussion 1266. doi: 10.1016/j.jtcvs.2013.06.029. Epub 2013 Aug 13. J Thorac Cardiovasc Surg. 2013. PMID: 23953984
-
Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.Circ Cardiovasc Qual Outcomes. 2020 Mar;13(3):e006275. doi: 10.1161/CIRCOUTCOMES.119.006275. Epub 2020 Mar 11. Circ Cardiovasc Qual Outcomes. 2020. PMID: 32156164
-
Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non-ST Elevation Myocardial Infarction: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines (NCDR ACTION Registry-GWTG).Circ Cardiovasc Qual Outcomes. 2016 May;9(3):197-205. doi: 10.1161/CIRCOUTCOMES.115.002084. Epub 2016 May 10. Circ Cardiovasc Qual Outcomes. 2016. PMID: 27166210
-
What Are Optimal P2Y12 Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndrome?J Cardiovasc Pharmacol Ther. 2020 Mar;25(2):121-130. doi: 10.1177/1074248419882923. Epub 2019 Oct 23. J Cardiovasc Pharmacol Ther. 2020. PMID: 31645108 Review.
-
Strategies to optimize initial P2Y12 inhibitor therapy in STEMI patients.Cardiovasc Revasc Med. 2025 Feb;71:43-49. doi: 10.1016/j.carrev.2024.09.012. Epub 2024 Sep 25. Cardiovasc Revasc Med. 2025. PMID: 39343662 Review.
Cited by
-
Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI.Crit Pathw Cardiol. 2020 Dec;19(4):166-172. doi: 10.1097/HPC.0000000000000243. Crit Pathw Cardiol. 2020. PMID: 32947379 Free PMC article.
-
Outcome of acute myocardial infarction versus stable coronary artery disease patients treated with coronary bypass surgery.Ann Med. 2021 Dec;53(1):70-77. doi: 10.1080/07853890.2020.1818118. Epub 2020 Sep 14. Ann Med. 2021. PMID: 32875916 Free PMC article.
-
Assessment of Pretreatment With Oral P2Y12 Inhibitors and Cardiovascular and Bleeding Outcomes in Patients With Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Meta-analysis.JAMA Netw Open. 2021 Nov 1;4(11):e2134322. doi: 10.1001/jamanetworkopen.2021.34322. JAMA Netw Open. 2021. PMID: 34797371 Free PMC article.
-
To Pretreat or Not to Pretreat (With Oral P2Y12 Antagonists)? That is the Question.J Am Heart Assoc. 2017 Sep 22;6(9):e007288. doi: 10.1161/JAHA.117.007288. J Am Heart Assoc. 2017. PMID: 28939720 Free PMC article. No abstract available.
-
Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective.Am J Cardiovasc Drugs. 2022 Jan;22(1):93-104. doi: 10.1007/s40256-021-00491-9. Epub 2021 Jul 31. Am J Cardiovasc Drugs. 2022. PMID: 34331235 Free PMC article. Clinical Trial.
References
-
- Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation. N Engl J Med. 2001;345:494–502. - PubMed
-
- Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F‐J, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015. - PubMed
-
- Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057. - PubMed
-
- Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non‐ST‐elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60:645–681. - PubMed
-
- Sherwood MW, Wiviott SD, Peng SA, Roe MT, DeLemos J, Peterson ED, Wang TY. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J Am Heart Assoc. 2014;3:e000849 DOI: 10.1161/JAHA.114.000849. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical